Why Diaspore exists

Academic labs are sitting on decades of research that nobody has searched, evaluated or acted on. Diaspore exists to find the science worth funding while it is still early.

The science is already there

Universities and research institutes publish papers, file patents and win grants every year. Most of that work is never read by anyone in a position to fund it. Some of it is new. Some of it has been on the shelf for decades. Either kind can become a medicine and a company.

Why early matters

A business development or venture team that backs a scientist early gets two things. It keeps the largest share of the return, because it arrives before the price reflects the science. And it reaches the most original work before the field is crowded, which is where the medicines that change care for patients tend to come from.

One example: GLP-1

The hormone behind today's diabetes and obesity medicines was worked out in academic labs in the nineteen-eighties. The first medicine in its class reached patients about two decades later. It came from a separate academic finding: a researcher at a veterans' hospital found a similar molecule in Gila monster venom, patented it himself, and spent three years looking for a company willing to take it on. Novo Nordisk and others then built the medicines now used for diabetes and obesity.

The science was public the whole time. What was missing was someone looking for it.

Sources: Journal of Clinical Investigation on the discovery of GLP-1; Biotech Academy on the Gila monster finding.

Why now

Reading the whole public record used to be impossible for any team. With AI it is not. When many teams are chasing the same early science, the advantage goes to whoever finds it first and judges it well. That is the work Diaspore does: it reads papers, grants, patents, trials and filings as they stood on a given date, points to the labs and young companies worth a look, and keeps a dated record so every call can be checked against what happened next.